Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
37
FDMT Quote, Financials, Valuation and Earnings
Last price:
$4.35
Seasonality move
:
-28.07%
Day range:
$4.19 - $4.41
52-week range:
$2.24 - $19.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10,531.44x
P/B ratio:
0.43x
Volume:
275.9K
Avg. volume:
443K
1-year change:
-76.04%
Market cap:
$202M
Revenue:
$37K
EPS (TTM):
-$3.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics
|
$522.8K | -$0.69 | 10356% | -10.03% | $31.10 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics
|
$4.36 | $31.10 | $202M | -- | $0.00 | 0% | 10,531.44x |
|
ATNM
Actinium Pharmaceuticals
|
$1.62 | $5.00 | $50.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.64 | -- | $26.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.43 | $1.00 | $1M | -- | $0.00 | 0% | 0.46x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics
|
-- | 2.781 | -- | 11.95x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics
|
-- | -$53.6M | -32.41% | -32.41% | -383007.14% | -$48.4M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
4D Molecular Therapeutics vs. Competitors
-
Which has Higher Returns FDMT or ATNM?
Actinium Pharmaceuticals has a net margin of -342657.14% compared to 4D Molecular Therapeutics's net margin of -11511.11%. 4D Molecular Therapeutics's return on equity of -32.41% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics-- -$0.86 $469.7M ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About FDMT or ATNM?
4D Molecular Therapeutics has a consensus price target of $31.10, signalling upside risk potential of 613.3%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 208.64%. Given that 4D Molecular Therapeutics has higher upside potential than Actinium Pharmaceuticals, analysts believe 4D Molecular Therapeutics is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics5 2 1 ATNMActinium Pharmaceuticals2 1 0 -
Is FDMT or ATNM More Risky?
4D Molecular Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock FDMT or ATNM?
4D Molecular Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or ATNM?
4D Molecular Therapeutics quarterly revenues are $14K, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. 4D Molecular Therapeutics's net income of -$48M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, 4D Molecular Therapeutics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics is 10,531.44x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics10,531.44x -- $14K -$48M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns FDMT or NBY?
NovaBay Pharmaceuticals has a net margin of -342657.14% compared to 4D Molecular Therapeutics's net margin of -49.65%. 4D Molecular Therapeutics's return on equity of -32.41% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics-- -$0.86 $469.7M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About FDMT or NBY?
4D Molecular Therapeutics has a consensus price target of $31.10, signalling upside risk potential of 613.3%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that 4D Molecular Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe 4D Molecular Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics5 2 1 NBYNovaBay Pharmaceuticals1 0 0 -
Is FDMT or NBY More Risky?
4D Molecular Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock FDMT or NBY?
4D Molecular Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or NBY?
4D Molecular Therapeutics quarterly revenues are $14K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 4D Molecular Therapeutics's net income of -$48M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, 4D Molecular Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics is 10,531.44x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics10,531.44x -- $14K -$48M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns FDMT or NNVC?
Nanoviricides has a net margin of -342657.14% compared to 4D Molecular Therapeutics's net margin of --. 4D Molecular Therapeutics's return on equity of -32.41% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics-- -$0.86 $469.7M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About FDMT or NNVC?
4D Molecular Therapeutics has a consensus price target of $31.10, signalling upside risk potential of 613.3%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 296.34%. Given that 4D Molecular Therapeutics has higher upside potential than Nanoviricides, analysts believe 4D Molecular Therapeutics is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics5 2 1 NNVCNanoviricides0 0 0 -
Is FDMT or NNVC More Risky?
4D Molecular Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock FDMT or NNVC?
4D Molecular Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or NNVC?
4D Molecular Therapeutics quarterly revenues are $14K, which are larger than Nanoviricides quarterly revenues of --. 4D Molecular Therapeutics's net income of -$48M is lower than Nanoviricides's net income of -$2.2M. Notably, 4D Molecular Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics is 10,531.44x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics10,531.44x -- $14K -$48M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns FDMT or OGEN?
Oragenics has a net margin of -342657.14% compared to 4D Molecular Therapeutics's net margin of --. 4D Molecular Therapeutics's return on equity of -32.41% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics-- -$0.86 $469.7M OGENOragenics-- -$3.60 -- -
What do Analysts Say About FDMT or OGEN?
4D Molecular Therapeutics has a consensus price target of $31.10, signalling upside risk potential of 613.3%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than 4D Molecular Therapeutics, analysts believe Oragenics is more attractive than 4D Molecular Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics5 2 1 OGENOragenics0 1 0 -
Is FDMT or OGEN More Risky?
4D Molecular Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock FDMT or OGEN?
4D Molecular Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or OGEN?
4D Molecular Therapeutics quarterly revenues are $14K, which are larger than Oragenics quarterly revenues of --. 4D Molecular Therapeutics's net income of -$48M is lower than Oragenics's net income of -$2.2M. Notably, 4D Molecular Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics is 10,531.44x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics10,531.44x -- $14K -$48M OGENOragenics0.46x -- -- -$2.2M
-
Which has Higher Returns FDMT or TOVX?
Theriva Biologics has a net margin of -342657.14% compared to 4D Molecular Therapeutics's net margin of --. 4D Molecular Therapeutics's return on equity of -32.41% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics-- -$0.86 $469.7M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About FDMT or TOVX?
4D Molecular Therapeutics has a consensus price target of $31.10, signalling upside risk potential of 613.3%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than 4D Molecular Therapeutics, analysts believe Theriva Biologics is more attractive than 4D Molecular Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics5 2 1 TOVXTheriva Biologics1 1 0 -
Is FDMT or TOVX More Risky?
4D Molecular Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock FDMT or TOVX?
4D Molecular Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or TOVX?
4D Molecular Therapeutics quarterly revenues are $14K, which are larger than Theriva Biologics quarterly revenues of --. 4D Molecular Therapeutics's net income of -$48M is lower than Theriva Biologics's net income of -$4.3M. Notably, 4D Molecular Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics is 10,531.44x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics10,531.44x -- $14K -$48M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
